RxDoctor Payments Data

Aamir Hameed, MD

Interventional Cardiology · Oklahoma City, OKNPI 1245241793

Payments from drug & device makers

$3,190in general payments, 2019–2025

Across 39 payments — averaging $81.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Medtronic$1K
  • Amgen$174
  • Shockwave Medical, Inc$147
  • Abiomed$117
  • E.r. Squibb & Sons, L.L.C.$114
  • plus $179 from 8 others

What the payments were for

  • Travel & lodging$2,32173%
  • Food & beverage$86927%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,190 in reported general payments places this provider in the 25th percentile of 110 interventional cardiology providers in Oklahoma.

See all interventional cardiology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$218,808
Medicare patients
808
Services billed
3,071

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban203$189,645
XareltoRivaroxaban61$64,301
Repatha SureclickEvolocumab75$43,624
JardianceEmpagliflozin39$36,931
BrilintaTicagrelor36$26,240
Atorvastatin Calcium831$16,804
ClopidogrelClopidogrel Bisulfate430$11,024
Pantoprazole Sodium141$6,174
Enalapril Maleate232$6,044
Ramipril395$5,114
Valsartan132$3,722
Rosuvastatin Calcium198$3,663
FenofibrateFenofibrate Nanocrystallized110$3,375
Metoprolol Succinate194$3,244
Ezetimibe98$2,867

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$189,645203 claims
AstraZenecaBrilinta$33$26,24036 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 110 interventional cardiology providers in Oklahoma.

Other interventional cardiology in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →